Lowering hemoglobin A1c level to less than 6.0% in people with type 2 diabetes may reduce major adverse cardiovascular events: a Bayesian’s narrative

Hui Shaoa Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA;b Center for Drug Evaluation and Safety (CoDES), University of Florida, Gainesville, FL, USA;c Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA, USACorrespondence[email protected]

Jingchuan Guoa Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA;b Center for Drug Evaluation and Safety (CoDES), University of Florida, Gainesville, FL, USA

Neda Laiteerapongd Department of Medicine, University of Chicago, Chicago, IL, USA

Shichao Tangc Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA, USA

Vivian Fonsecae Department of Medicine and Pharmacology, School of Medicine, Tulane University, New Orleans, LA, USA

Lizheng Shif Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA

Ping Zhangc Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA, USA

show all

References

Reaven PD, Emanuele NV, Wiitala WL, VADT Investigators, et al. Intensive glucose control in patients with type 2 diabetes — 15-year follow-up. N Engl J Med. 2019;380(23):2215–2224.
PubMed Web of Science ®Google Scholar
The ACCORD Study Group Nine-Year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care. 2016;39(5):701–708.
PubMed Web of Science ®Google Scholar
Brophy JM. Bayesian interpretation of the EXCEL trial and other randomized clinical trials of left main coronary artery revascularization. JAMA Intern Med. 2020;180(7):986–992.
PubMed Web of Science ®Google Scholar
Wijeysundera DN, Austin PC, Hux JE, et al. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials. J Clin Epidemiol. 2009;62(1):13–21.e5.
PubMed Web of Science ®Google Scholar
Shao H, Fonseca V, Stoecker C, et al. Novel risk engine for diabetes progression and mortality in USA: building, relating, assessing, and validating outcomes (BRAVO). Pharmacoeconomics. 2018;36(9):1125–1134.
PubMed Web of Science ®Google Scholar
Shao H, Yang S, Stoecker C, et al. Addressing regional differences in diabetes progression: global calibration for diabetes simulation model. Value Health. 2019;22(12):1402–1409.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Lowering hemoglobin A1c level to less than 6.0% in people with type 2 diabetes may reduce major adverse cardiovascular events: a Bayesian’s narrative

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Lowering hemoglobin A1c level to less than 6.0% in people with type 2 diabetes may reduce major adverse cardiovascular events: a Bayesian’s narrative

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date